Thus, our data showed that consistent with increased doxorubicin retention, knockdown of ABCC3 also reduces the IC50 for chemotherapeutic drugs, much more than the ABCC1 knockdown, suggesting that inhibition or preventing the upregulation of ABCC3 might be efficacious for breast cancer treatment. This evidence concerns the gene ABCC3 and breast cancer.